Anavex Life Sciences Corp (AVXL)

[nidan7500]

Blarcasamine

Can someone please explain what this patent really means and how it differs from some of the other patents we have seen come out of Anavex for 273. Is this a patent to go after a basket trial? Does this patent do something different that some of the other patents that we seen protecting the IP for blarcamisine? I like 2037 but just not sure what this one is doing. Thanks/[ quote]

Think of it as the AVXL MOA patent. This is a broad departure from the meds of the past-site-disease specific. IMO, this gets at the CNS (system) , which is the path we are on, unlike competitors and which has frequently been pointed to by Dr. M. and team . IMO, this is a pointer to the new (next 20+ yrs)...medical serial thinking process. (others here more qualified to carry the concepts ref; Falconer for example) . I do recognize a systems message when I see one and this is a massive headlines to BP serial thinking ...say BAAH...BYE Boys.

My guess is Dr..M. has presented and will prove by AI-Vis-other strong evidence w/trial data to close the lid on past Bio-Med-Pharma old school thinking. He just threw a blanket over BioMed futures. The good news is, they still do not get it, All they can hope for is some kind of multiple partnerships w/AVXL going fwd...IMO.

This kind of PAT approval. is as much about BP-product-structure and portfolio obsolescence as it is about the controls going forward. Listen for the GIANT .."OHHH SHAT"...themes going fwd.